Tailor treatment of type 2 diabetes to improve cardiovascular outcomes
Karen Bartha discusses the Association of British Clinical Diabetologists position statement on the use of newer antidiabetic drugs in patients with cardiovascular disease
Manage diabetes and comorbidities with a joined-up strategy
Dr Umesh Dashora and colleagues from the CaReMeUK Partnership outline guidance on how to manage type 2 diabetes with cardiovascular and renal disease
Diabetes in chronic kidney disease requires practical, evidence-based care
Dr Pam Brown and Dr Colin Kenny discuss recommendations from a new international guideline on diabetes management in patients with chronic kidney disease
Type 2 diabetes: maintain glycaemic control to prevent complications
Dr Samuel Seidu and Professor Kamlesh Khunti discuss the recommendations of the Primary Care Diabetes Europe position statement on the management of type 2 diabetes
Diagnose and treat pancreatic exocrine insufficiency in diabetes
Dr Kate Millar and Professor Michael Cummings present a summary of guidance that aims to help practitioners to identify and manage pancreatic exocrine insufficiency in people with diabetes
Test and reflect
Our multiple-choice questions (MCQs) are designed to help you test your knowledge and reflect on your learning after reading an article.
ABCD guideline on type 2 diabetes and cardiovascular outcomes
CaReMeUK guideline on the management of diabetes and comorbidities
Patient scenarios: CaReMeUK guidance on the management of diabetes and comorbidities
Patient scenarios: KDIGO guideline on diabetes and CKD
KDIGO guideline on chronic kidney disease and diabetes
Educational resources
Dipeptidyl peptidase-4 inhibitors—still a major player in type 2 diabetes care
This promotional supplement has been commissioned and funded by Boehringer Ingelheim Ltd and developed in partnership with Guidelines in Practice.
View Trajenta® (linagliptin) prescribing and adverse event reporting information
PC-GB-103451 Date of preparation: January 2021
Guideline for the managed introduction of biosimilar basal insulin
This working party guideline was developed by a multidisciplinary expert panel: Down S et al with the support of a grant from Mylan.